Skip to main content

Table 3 Interventions, results and GRADE of studies included in the review

From: Effect of stem cell treatment on functional recovery of spinocerebellar ataxia: systematic review and meta-analysis

Author/year Interventions Relevant statistical data Grade
Dongmei et al., 2011 [19] UCMSCs (1 × 106 /kg; 10 mL) with 5 mg dexamethasone was injected intrathecally weekly for 4 weeks by lumbar punctures, resulting in 4 injections for 4 weeks. ICARS = ↑ posture, gait disorders, coordination, speech disorders, ocular motility. ADL = ↑ self-care ability.  ϴϴ
Low
Jin et al., 2013 [20] UCMSCs (4 × 107) in 30 ml saline solution IV in 30 min and 3 treatments, 2 × 107 in 30 ml IV and 2 × 107 in 1 ml IT simultaneously. 4 applications a week apart. After the first application of UCMSCs, 38% (6/16) ↑ BBS. From 3 to 6 months 63% (10/16) ↑ BBS and there were statistically significant improvements over the baseline. After 1-year 7/16 (44%) ↑ BBS over the baseline, and only 5/16 (31%) of the patients suffered from the disease. ↑ ICARS in the 3rd and 6th month.  ϴϴ
Low
Tsai et al., 2017 [21] 100 g of adipose tissue was collected by liposuction of the abdominal region of two healthy donors. The AD-MSC were frozen at a concentration of 7 × 107 viable cells in 20 ml of cryopreservation solution. On the day of infusion, thawed AD-MSCs were mixed with 100 ml with normal saline and administered IV in 40 min. SARA score evolution: 13.25 at the baseline, 13.0 in the first 15 days, 12.75 at 6 months, and 13.5 at 12 months.  ϴϴ
Low
  1. UCMSC Umbilical cord mesenchimal stem cells, ICARS Intarnational Cooperative Ataxia Rading Scale, ADL Activity of Daily Living Scale, IT Intrathecal, BBS Berg Balance Scale, AD-MSCs Adipose tissue mesenchimal stem cells, IV Intravenous, SARA Scale for the Assessment and Randing of Ataxia